Hepatorenal Syndrome and Efficiency of Aldosterone Receptor Blockade in Experimentally Bile Duct Ligated Dogs
World Small Animal Veterinary Association World Congress Proceedings, 2003
R. Gonul; U. Bakirel; A. Kayar; Y. Meral; M.E. Or; G. Sennazli; A. Gurel; E. Akdenizli
Veterinary Faculty, Istanbul University, Department of Internal Medicine,
Avcilar-Istanbul, Turkey

Objectives

In this study, the effects of an aldosterone antagonist on the hepatorenal system and systemic hemodynamics in common bile duct ligated (CBL) dogs were investigated.

Materials & Methods

CBL dogs (n=14) and the sham operated but no ligated dogs (n=14) were again divided into two groups for giving a derivative of spironolactone (ALDOCTAN® tablet), at 1.5 mg/kg daily for six weeks. Hepatorenal changes and systemic effects of medicine were observed with necessary checkings and by comparing of control and test groups in the decompensation period which occurred on 4-6 weeks of hepatic cirrhosis.

Results

It was determined that, after the operation the serum levels of ALT, AST, T.Biluribin, D.Biluribin, ALP and GGT increased statistically significantly (p<0.001-0.05) the serum levels of T.Protein and albumin decreased in all dogs. It was observed that the serum levels of aldosterone, Na and K were within the normal limits and the systemic hemodynamics and the heart rate were the same in all groups. At the other hand, glomerular filtration rate which evaluated with serum Cystatin C level, was decreased specially non-aldactonized cirrhotic dogs.

Conclusion

It was determined that the aldosterone receptor antagonists prevent decrease of the glomerular filtration rate even in early stage so that it can be useful to prevent the edema and ascites in cirrhotic dogs.

Speaker Information
(click the speaker's name to view other papers and abstracts submitted by this speaker)

R. Gonul
Department of Internal Medicine, Veterinary Faculty, Istanbul University
Avcilar-Istanbul, Turkey


MAIN : Oral Presentations : Hepatorenal Syndrome
Powered By VIN

Friendly Reminder to Our Colleagues: Use of VIN content is limited to personal reference by VIN members. No portion of any VIN content may be copied or distributed without the expressed written permission of VIN.

Clinicians are reminded that you are ultimately responsible for the care of your patients. Any content that concerns treatment of your cases should be deemed recommendations by colleagues for you to consider in your case management decisions. Dosages should be confirmed prior to dispensing medications unfamiliar to you. To better understand the origins and logic behind these policies, and to discuss them with your colleagues, click here.

Images posted by VIN community members and displayed via VIN should not be considered of diagnostic quality and the ultimate interpretation of the images lies with the attending clinician. Suggestions, discussions and interpretation related to posted images are only that -- suggestions and recommendations which may be based upon less than diagnostic quality information.

CONTACT US

777 W. Covell Blvd., Davis, CA 95616

vingram@vin.com

PHONE

  • Toll Free: 800-700-4636
  • From UK: 01-45-222-6154
  • From anywhere: (1)-530-756-4881
  • From Australia: 02-6145-2357
SAID=27